![]() |
市场调查报告书
商品编码
1476369
2030 年吸入药物市场预测:按药物类别、分销管道、应用和区域分類的全球分析Inhalable Drugs Market Forecasts to 2030 - Global Analysis By Drug Class, Distribution Channel, Application and By Geography |
根据 Stratistics MRC 的数据,2023 年全球吸入药物市场规模为 343 亿美元,预计到 2030 年将达到 619 亿美元,预测期内复合年增长率为 8.8%。
吸入药物市场包括透过吸入途径输送的针对呼吸道和全身疾病的药物。吸入剂直接进入呼吸系统,可以快速吸收到血液中并局部治疗效果。吸入药物市场在现代医学中发挥重要作用,为各种呼吸系统疾病和全身性疾病的治疗提供创新的解决方案。吸入药物经由吸入器或雾化器给药,可快速、有针对性地直接输送至呼吸系统,确保有效吸收和起效。
根据美国疾病管制与预防中心(CDC)预测,2021年美国将有超过2,500万人患有气喘,约占成人的8.0%和儿童的6.5%。世界卫生组织(WHO)2022年10月发表的论文显示,全球整体,从2015年的12%增至2050年的22%,备受关注。
呼吸道疾病增加
气喘、慢性阻塞性肺病(COPD)和囊肿纤维化等呼吸系统疾病的盛行率不断上升,推动了吸入器市场的显着成长。随着这些疾病在世界各地变得越来越普遍,对有效治疗方案的需求不断增长。与传统口服药物相比,吸入药物具有多种优势,包括直接靶向输送至肺部、起效快以及较少的全身副作用。此外,吸入技术的进步促进了创新输送设备的发展,提高了患者的便利性和对治疗方法的依从性。
滥用吸入器的风险
吸入剂可能会被故意滥用于休閒目的,或因给药技术不当而无意中滥用。存在滥用的可能性,尤其是精神活性药物。这种滥用不仅会损害治疗效果,还会引起对病人安全和监管合规性的担忧。因此,医疗保健提供者和监管机构强调严格的监控和教育,以降低滥用风险,这可能会限制市场扩张。
生技药品吸入给药的可能性
吸入式生技药品製剂的出现透过提供更有效、对患者友善的给药方法,显着增强了吸入式药物市场。生技药品是源自生物体的大分子,彻底改变了气喘、慢性阻塞性肺病(COPD) 和囊肿纤维化等各种慢性疾病的治疗模式。吸入生物製药的可能性提供了一种非侵入性、无针头的选择,使它们能够直接施用到肺部,而许多呼吸道疾病都发生在肺部。这不仅提高了患者的舒适度和依从性,而且有可能透过有针对性的给药和减少全身副作用来改善治疗结果。
开发成本高
高开发成本是吸入器市场的主要障碍,抑制了创新和新产品的推出。吸入药物的复杂开发过程涉及广泛的研究、临床试验和监管核准,所有这些都需要高昂的成本。製药公司经常面临平衡这些高成本与潜在市场需求和盈利的挑战。然而,吸入给药系统的复杂性需要先进的技术和专业知识,进一步加剧了不断飙升的开发成本。
随着病毒向呼吸系统的传播,呼吸药物输送系统受到关注,对吸入药物的需求增加。对呼吸困难等 COVID-19 症状的有效治疗方法的需求导致了吸入药物的研发激增。封锁和社会疏离措施扰乱了供应链和分销网络,导致生产和分销暂时受挫。医疗保健系统优先考虑了 COVID-19 的管理,转移了人们对其他医疗疾病(包括通常使用吸入药物治疗的呼吸道疾病)的注意力和资源。
预计白三烯改质剂部分在预测期内将是最大的
预计白三烯改质剂部分在预测期内将是最大的。透过针对白三烯介导的发炎途径,这些药物提供了一种治疗呼吸系统疾病的新方法,特别是影响全世界数百万人的气喘。与传统的支气管扩张剂不同,白三烯调节剂透过抑制白三烯的产生或作用来发挥作用,从而抑制气道发炎和收缩。这种机制不仅可以缓解症状,还有助于预防气喘恶化并改善整体肺功能。
预计零售药局领域在预测期内复合年增长率最高
零售药房领域预计在预测期内复合年增长率最高。这是因为这些药房是可到达的分销中心,使消费者可以轻鬆获得吸入药物。随着气喘和慢性阻塞性肺病等呼吸系统疾病的盛行率不断增加,在附近药局购买吸入器非常方便,可以显着提高患者对治疗方法的依从性。此外,零售药局经常提供病患教育和咨询服务,以协助正确的吸入技术和药物管理。此外,零售药局作为技术创新中心,储备新的吸入製剂和药物传输设备,透过响应不断变化的患者需求和偏好来推动市场成长。
预计亚太地区在预测期内将占据最大的市场份额。该地区国家正在增加对医疗基础设施和服务的投资,并更加关注创新的药物输送系统,包括吸入药物。中等收入人口的增长和生活方式的改变导致呼吸系统疾病的增加,进一步推动了该地区对吸入器的需求。亚太地区的医疗保健支出持续飙升,製药公司越来越多地投资于吸入药物製剂的研发,推动了该地区吸入药物市场的成长。
预计亚太地区在预测期内将呈现良好的成长动能。亚太地区的政府法规透过营造有利于创新、安全和可近性的环境,在加强吸入器市场方面发挥关键作用。药品註册核准流程和製造标准等法律规范确保吸入药物在进入市场之前符合严格的品质和功效标准。因此,政府法规不仅保护了公众健康,也促进了亚太地区吸入器市场的成长。
According to Stratistics MRC, the Global Inhalable Drugs Market is accounted for $34.3 billion in 2023 and is expected to reach $61.9 billion by 2030 growing at a CAGR of 8.8% during the forecast period. The inhalable drugs market encompasses pharmaceutical products delivered through inhalation routes, targeting respiratory conditions or systemic diseases. Inhalable drugs are administered directly to the respiratory system, allowing for rapid absorption into the bloodstream and localized therapeutic effects. The inhalable drugs market serves as a vital avenue in modern medicine, offering innovative solutions for the treatment of various respiratory diseases and systemic conditions. Inhalable drugs, administered through inhalers or nebulizers, provide rapid and targeted delivery directly to the respiratory system, ensuring efficient absorption and onset of action.
According to the Centers for Disease Control and Prevention (CDC), more than 25 million people had asthma in the U.S. in 2021, accounting for approximately 8.0% of adults and 6.5% of children. According to an article released by the World Health Organization in October 2022, globally, the percentage of individuals aged 60 years and above is likely to increase twofold from 12% in 2015 to 22% by 2050.
Rising prevalence of respiratory diseases
The increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis has spurred significant growth in the inhalable drugs market. As these conditions become more prevalent globally, the demand for effective treatment options has escalated. Inhalable drugs offer several advantages over traditional oral medications, including targeted delivery directly to the lungs, rapid onset of action, and reduced systemic side effects. Additionally, advancements in inhalation technology have led to the development of innovative delivery devices, improving patient convenience and adherence to treatment regimens.
Risk of misusing inhalable medications
Inhalers can be misused intentionally for recreational purposes or unintentionally due to improper administration techniques. There's a potential for abuse, particularly with medications that have psychoactive effects. Such misuse not only compromises the effectiveness of the treatment but also raises concerns regarding patient safety and regulatory compliance. Consequently, healthcare providers and regulatory agencies emphasize stringent monitoring and education to mitigate the risk of misuse, which can potentially limit the market's expansion.
Possibility of inhaling biologics delivery
The emergence of inhalable biologics delivery has significantly bolstered the Inhalable Drugs Market by offering a more efficient and patient-friendly administration method. Biologics, which are large molecules derived from living organisms, have revolutionized the treatment landscape for various chronic conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. The possibility of inhaling biologics presents a non-invasive, needle-free alternative, allowing for direct delivery to the lungs where many respiratory diseases originate. This not only enhances patient comfort and adherence but also potentially improves therapeutic outcomes through targeted delivery and reduced systemic side effects.
High development costs
High development costs act as a significant barrier in the inhalable drugs market, impeding innovation and the introduction of new products. The intricate process of developing inhalable drugs involves extensive research, clinical trials, and regulatory approvals, all of which incur substantial expenses. Pharmaceutical companies often face the challenge of balancing these high costs with potential market demand and profitability. However, the complexity of inhalable drug delivery systems necessitates sophisticated technologies and expertise, further contributing to elevated development expenses.
With the respiratory nature of the virus, there was an increased focus on respiratory drug delivery systems, driving demand for inhalable drugs. The need for effective treatments for Covid-19 symptoms, such as respiratory distress, led to a surge in research and development of inhalable medications. Lockdowns and social distancing measures disrupted the supply chain and distribution networks, causing temporary setbacks in production and distribution. Healthcare systems prioritized Covid-19 management, diverting attention and resources away from other medical conditions, including respiratory diseases typically treated with inhalable drugs.
The leukotriene modifiers segment is expected to be the largest during the forecast period
Leukotriene Modifiers segment is expected to be the largest during the forecast period. By targeting the inflammatory pathway mediated by leukotrienes, these medications offer a novel approach to managing respiratory conditions, particularly asthma, which affects millions worldwide. Unlike traditional bronchodilators, leukotriene modifiers work by inhibiting the production or action of leukotrienes, thereby reducing airway inflammation and constriction. This mechanism not only provides symptom relief but also helps in preventing asthma exacerbations and improving overall lung function.
The retail pharmacies segment is expected to have the highest CAGR during the forecast period
Retail Pharmacies segment is expected to have the highest CAGR during the forecast period as these pharmacies serve as accessible points of distribution, making inhalable drugs readily available to consumers. With the increasing prevalence of respiratory ailments like asthma and COPD, the convenience of obtaining inhalable medications from nearby pharmacies significantly improves patient adherence to treatment regimens. Moreover, retail pharmacies often offer patient education and counseling services, aiding in proper inhaler technique and medication management. Furthermore, retail pharmacies serve as hubs for innovation, stocking new inhalable drug formulations and delivery devices, thus driving market growth by catering to evolving patient needs and preferences.
Asia Pacific region is expected to hold the largest share of the market over the projected period. As countries in the region invest more in healthcare infrastructure and services, there is an increased focus on innovative drug delivery systems, including inhalable drugs. The growing middle-class population and changing lifestyles contribute to the rise in respiratory disorders, further driving the demand for inhalable drugs in the region. With healthcare spending continuing to surge in Asia Pacific, pharmaceutical companies are increasingly investing in research and development of inhalable drug formulations, thus propelling the growth of the inhalable drugs market in the region.
Asia Pacific region is estimated to witness profitable growth during the extrapolated period. Government regulations in the Asia Pacific region have played a substantial role in enhancing the Inhalable Drugs Market by fostering a favorable environment for innovation, safety, and accessibility. Regulatory frameworks, such as the approval processes for drug registration and manufacturing standards, ensure that inhalable drugs meet stringent quality and efficacy standards before entering the market. As a result, government regulations have not only safeguarded public health but also catalyzed the growth of the inhalable drugs market in the Asia Pacific region.
Key players in the market
Some of the key players in Inhalable Drugs market include AstraZeneca, Boehringer Ingelheim International GmbH, Cipla Inc, GlaxoSmithKline plc, Merck & Co., Inc, Mundipharma International, Novartis International AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Vectura Group Ltd and Viatris Inc.
In November 2023, Sanofi, a pharmaceutical company, announced that Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating U.S. Food and Drug Administration submission and confirming potential to become first approved biologic for this serious disease
In July 2023, Viatris Inc., a global healthcare company, and Kindeva Drug Delivery L.P., a pharmaceutical contract development and manufacturing organization, launched Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first generic version of AstraZeneca's Symbicort with an abbreviated new drug application (ANDA) approved by the U.S. Food and Drug Administration (FDA).
In January 2023, AstraZeneca received approval from the U.S. Food and Drug Administration for Airsupra (albuterol and budesonide) inhalation aerosol. Airsupra aims to reduce the risk of asthma exacerbations in individuals aged 18 years and older.
In November 2022, PT027 had been recommended by the U.S.FDA Advisory Committee as new rescue treatment for asthma. T027 is a potential first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication in the U.S. containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS). It is being developed by AstraZeneca, a pharmaceutical company and Avillion, a global drug development company.
In March 2022, Viatris Inc. and Kindeva Drug Delivery L.P. received FDA approval for Breyna, a drug-device combination therapy recommended for patients with asthma or chronic obstructive pulmonary disease (COPD).